Zinc Ion

Zinc Ion

SCHEMBL428649

CCS(=O)(=O)[O-].CCS(=O)(=O)[O-].[Zn+2]

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

FGFR1FGFR2FGFR3FGFR4FLT1FLT4KDRPDGFRAPDGFRB

The experimentally established mechanism targets of Zinc Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BBOX1 O75936 3/20 0.38
KDM4E B2RXH2 2/20 0.37
MAPT P10636 1/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 3/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPK1 P28482 2/20 0.33
TP53 P04637 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
GMNN O75496 1/20 0.33
LMNA P02545 1/20 0.33
THPO P40225 1/20 0.33
HBB P68871 1/20 0.33
PMP22 Q01453 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
RECQL P46063 2/20 0.32
GLA P06280 1/20 0.32
HPGD P15428 1/20 0.32
EPHX2 P34913 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL22581629 0.96 BBOX1 (0.36) BBOX1KDM4EMAPTALOX15TSHR
SCHEMBL9001604 0.91 BBOX1 (0.38) BBOX1KDM4EMAPTALOX15TSHR
SCHEMBL20583852 0.91 BBOX1 (0.38) BBOX1KDM4EMAPTALOX15TSHR
SCHEMBL2367141 0.91 BBOX1 (0.38) BBOX1KDM4EMAPTALOX15TSHR
SCHEMBL22581623 0.91 BBOX1 (0.38) BBOX1KDM4EMAPTALOX15TSHR
SCHEMBL20533681 0.91 BBOX1 (0.38) BBOX1KDM4EMAPTALOX15TSHR
SCHEMBL20533678 0.91
SCHEMBL20533647 0.91 BBOX1 (0.38) BBOX1KDM4EMAPTALOX15TSHR
SCHEMBL1552464 0.91 BBOX1 (0.38) BBOX1KDM4EMAPTALOX15TSHR
SCHEMBL19809549 0.91 BBOX1 (0.38) BBOX1KDM4EMAPTALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110010373-B Electrode zinc embedding treatment method and application thereof in preparation of battery type super capacitor 中国科学院福建物质结构研究所 2021-02-19 CN claimed
CN-109994322-B Battery type super capacitor and application thereof 中国科学院福建物质结构研究所 2020-12-29 CN claimed
CN-109037794-B Rechargeable battery 刘小林 2020-11-24 CN claimed
US-20200343595-A1 RECHARGEABLE BATTERY LIU, XIAOLIN (CN) 2020-10-29 US claimed
CN-107910195-B Hybrid super capacitor 刘小林 2020-07-28 CN claimed
CN-109037794-A Rechargeable battery 南京蔚速科技有限公司 2018-12-18 CN claimed
US-20130059885-A1 Method For Preparation Of Pitavastatin and Pharmaceutical Acceptable Salts Thereof CADILA HEALTHCARE LIMITED (IN) 2013-03-07 US claimed
US-20120022102-A1 METHOD FOR PREPARATION OF PITAVASTATIN AND ITS PHARMACEUTICAL ACCEPTABLE SALTS THEREOF CADILA HEALTHCARE LIMITED (IN) 2012-01-26 US claimed
WO-2011089623-A2 PROCESS FOR PREPARING PITAVASTATIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF CADILA HEALTHCARE LIMITED (IN) 2011-07-28 WO claimed
WO-2009047577-A1 PROCESS FOR PREPARATION OF ROSUVASTATIN ZINC SALT EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság (HU) 2009-04-16 WO claimed
CN-121260953-A Electrolyte and zinc ion battery 北京中科行发医疗科技有限公司 2026-01-02 CN disclosed
CN-118589062-A Vanadium-based water-based zinc ion battery 北京化工大学 2024-09-03 CN disclosed
CN-110010373-B Electrode zinc embedding treatment method and application thereof in preparation of battery type super capacitor 中国科学院福建物质结构研究所 2021-02-19 CN disclosed
CN-109994322-B Battery type super capacitor and application thereof 中国科学院福建物质结构研究所 2020-12-29 CN disclosed
CN-109037794-B Rechargeable battery 刘小林 2020-11-24 CN disclosed
US-20120022102-A1 METHOD FOR PREPARATION OF PITAVASTATIN AND ITS PHARMACEUTICAL ACCEPTABLE SALTS THEREOF CADILA HEALTHCARE LIMITED (IN) 2012-01-26 US disclosed
WO-2011089623-A2 PROCESS FOR PREPARING PITAVASTATIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF CADILA HEALTHCARE LIMITED (IN) 2011-07-28 WO disclosed
US-6830704-B2 Contains a Lewis acid metal salt and a compound having clathrating ability. TOAGOSEI CO., LTD. (JP) 2004-12-14 US disclosed
US-20030135016-A1 Contains a Lewis acid metal salt and a compound having clathrating ability. TOAGOSEI CO., LTD. 2003-07-17 US disclosed
US-6547985-B1 Adhesive mixture TOGOSEI CO., LTD. (JP) 2003-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059885-A1 Method For Preparation Of Pitavastatin and Pharmaceutical Acceptable Salts Thereof GANAB, SLC30A5, TPP1 BBOX1 3824/4885KDM4E 1009/4885MAPT 2105/4885
US-20120022102-A1 METHOD FOR PREPARATION OF PITAVASTATIN AND ITS PHARMACEUTICAL ACCEPTABLE SALTS THEREOF GANAB, SLC30A5, TPP1 BBOX1 3370/4885KDM4E 781/4885MAPT 2342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.